PUBLISHER: The Business Research Company | PRODUCT CODE: 1942645
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942645
Deep brain stimulation (DBS) devices are specialized medical instruments designed to administer electrical currents directly to specific areas of the brain. These electrical impulses serve to address chemical imbalances within the brain that may contribute to various neuropsychological disorders. DBS is a therapeutic approach employed for the treatment of these conditions.
The primary product types within the category of deep brain stimulation devices are single-channel deep brain stimulators and dual-channel deep brain stimulators. A single-channel deep brain stimulator is a medical device specifically engineered to deliver electrical currents directly to targeted areas of the brain. These devices find application in addressing a range of conditions, including epilepsy, essential tremor, obsessive-compulsive disorder (OCD), depression, dystonia, Parkinson's disease, and pain management. These devices are utilized in various healthcare settings such as hospitals, neurology clinics, ambulatory surgical centers, and research centers.
Tariffs are impacting the deep brain stimulation device market by increasing costs of imported electronic components, microprocessors, medical-grade metals, and precision manufacturing equipment used in implantable pulse generators and electrode systems. North America and Europe are most affected due to reliance on cross-border sourcing of high-value components, while Asia-Pacific faces cost pressures on device exports. These tariffs are increasing overall device prices and procurement costs for hospitals. However, they are also encouraging localized manufacturing, regional supply chain diversification, and investment in domestic medical device production capabilities.
The deep brain stimulation device market research report is one of a series of new reports from The Business Research Company that provides deep brain stimulation device market statistics, including deep brain stimulation device industry global market size, regional shares, competitors with a deep brain stimulation device market share, detailed deep brain stimulation device market segments, market trends and opportunities, and any further data you may need to thrive in the deep brain stimulation device industry. This deep brain stimulation device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The deep brain stimulation device market size has grown rapidly in recent years. It will grow from $1.7 billion in 2025 to $1.9 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, wider clinical acceptance of deep brain stimulation, expansion of neurosurgical specialty centers, improved safety profiles of implantable devices, availability of advanced neuroimaging technologies.
The deep brain stimulation device market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to growing focus on precision neuromodulation therapies, rising investments in neurotechnology research, expansion of indications beyond movement disorders, increasing adoption of remote programming capabilities, continuous innovation in implantable electronics. Major trends in the forecast period include increasing adoption of closed-loop neurostimulation systems, rising demand for personalized dbs programming, growing use of rechargeable implantable pulse generators, expansion of image-guided electrode placement techniques, enhanced focus on minimally invasive neurosurgical procedures.
The anticipated growth in the deep brain stimulation (DBS) device market is expected to be propelled by the increasing prevalence of neurological diseases. Neurological disorders, affecting the central and peripheral nervous systems, can be effectively addressed by DBS devices, which are designed to regulate abnormal brain activity and rectify chemical imbalances contributing to various conditions. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections indicating this could rise to 13.8 million by 2060. This surge in neurological disorders is a significant driver behind the growth of the deep brain stimulation device market.
Leading companies in the deep brain stimulation device market are focusing on technological advancements, including connected care technology, to improve patient care by enabling remote programming, enhancing communication between patients and healthcare providers, and optimizing treatment outcomes for individuals with movement disorders. Connected care technology involves the integration of digital tools and platforms that promote continuous communication and data exchange between patients and healthcare providers, thereby enhancing patient monitoring, treatment management, and overall healthcare delivery. For example, in January 2024, Abbott Laboratories, a U.S.-based healthcare and medical device company, received approval from the U.S. Food and Drug Administration for the Liberta RC DBS system, which is the smallest rechargeable deep brain stimulation device designed for treating movement disorders. Key features of the Liberta RC DBS system include remote programming capabilities via the NeuroSphere Virtual Clinic, a requirement of only 10 recharges per year, and a compact design that is 31% smaller than competing devices. Additionally, it features a wireless charging system that can recharge the device every 37 days and offers customizable controls through an Abbott patient controller or compatible iOS devices.
In September 2023, Amber Therapeutics, a US-based healthcare technology company, acquired Bioinduction Limited for an undisclosed amount. Through this acquisition, Amber Therapeutics aims to strengthen its technological capabilities and speed the development of its closed-loop neuromodulation therapy for mixed urinary incontinence. Bioinduction Limited is a UK-based healthcare technology company that specializes in deep brain stimulation (DBS) devices.
Major companies operating in the deep brain stimulation device market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova plc, Aleva Neurotherapeutics SA, Beijing PINS Medical Co. Ltd., SceneRay Corporation, MicroPort NeuroTech, Precisis AG, Neuralink Corporation, Sapiens Neuro, Functional Neuromodulation Ltd., Deep Brain Innovation LLC, Renishaw plc, NeuroOne Medical Technologies Corporation, CorTec GmbH, INBRAIN Neuroelectronics S.L., Synchron Inc., Rune Labs Inc., CereGate GmbH
North America was the largest region in the deep brain stimulation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep brain stimulation devices market report during the forecast period. The regions covered in the deep brain stimulation device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the deep brain stimulation device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The deep brain stimulation devices market consists of sales of neurostimulators, leads, extensions, and handheld controllers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Deep Brain Stimulation Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses deep brain stimulation device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for deep brain stimulation device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The deep brain stimulation device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.